Our Steps to Translating Visions into Realities

Global Leader in Genome-based Personalized Medicine

Leading Innovative Genomic Biotechnology

Our Work Does Not End Genomics, Promising Impact for Our Communities

Theragen is a comprehensive pharmaceutical and biotechnology group
Providing outstanding genetic analysis services and progressing personalized new drug development
Bio Medical Science &
Technology Division
Read More
Genome Analysis, NGS
Customized Diagnostic Solutions
Medical Big Data
Pharmaceutical DivisionRead More
Production & supply of medicines
Orphan Drug Development
Manufacturing & distributing IMD

Holding of core competence for precision medicine era The paradigm of future medicine in the fourth industrial revolution era is shifting with personalized “precision medicine” at the center. Theragen Etex receives more attention because it has both gene analysis ability and personalized drug development capability, which are core technologies for “precision medicine.”

The world’s highest level of genome analysis technology Theragen Etex has made excellent achievements using innovative technologies such as the creation of the world’s first female/tiger/minke whale genome maps and completion of the first domestic human genome map, holding the largest domestic genome analysis performance, and first commercialization of individual genome analysis service in Asia. The company is now poised to benefit from the new growth engine.

International GMP certified facilities, stable manufacturing and supply of medicines Pharmaceutical Division increased production facilities, acquired GMP certification from international consultative group, Pharmaceutical Inspection Cooperation/Scheme (PIC/S), and now stably manufactures and supplies medicines with its distribution affiliated companies. It also actively conducts research for securing a new drug pipeline such as incrementally modified drugs (IMD) or orphan drugs.

Carcinogenic gene analysis and development of novel anticancer drug With the cooperation of the world’s best research institutes and medical staff, we analyze variations in carcinogenic genes such as stomach cancer, liver cancer, head and neck cancers, and breast cancer and disease mechanisms. Vactosertib, a novel anticancer drug that we are developing, is under clinical trial in Korea and the US.

About Us Group companies make efforts to achieve a healthier and happier tomorrow.


24Jul MedPacto Announces Clinical Collaboration with MSD to Evaluate Vactosertib in combination with KEYTRUDA® (pembrolizumab)

MedPacto, Inc. a subsidiary of Theragen Etex, a genome-based drug discovery and clinical-stage biotechnology company, announced today that it has entered into a clinical collaboration agreement with Merck & Co., Inc., Ke...

24Jul MedPacto Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca

Collaboration will evaluate combination of MedPacto’s TGF-β type I receptor inhibitor, vactosertib (TEW-7197) with AstraZeneca’s durvalumab in a Phase I/II study for patients with NSCLC.   MedPacto, Inc. (“MedPacto...

18Jul Identify the cause of recurrence of pediatric brain tumor using genetic analysis technique

Theragen Etex has developed a technique, which can identify the cause of recurrence of pediatric brain tumor, using genetic analysis technique.   A team, led by professors from Seoul National University Hospital an...

29Jun Genome Care to provide 2 infertility aid services

Genome Care, a subsidiary of Theragen Etex, said that it plans to launch two new inspection services that can increase the implantation rate of artificial insemination in infertile women.   The two services are end...

21Jun Wins patent for immunotherapy research using big data

Theragen Etex has registered a patent regarding the use of big data technology in immunotherapy research.   This is the first time that a domestic biotech company obtained a patent in the field of providing biometr...

07Jun Medpacto to unveil P1 clinical trial on immunotherapy

Medpacto presents its phase 1 clinical trial results on Vactosertib, an immunotherapy agent, during the upcoming 2018 American Society of Clinical Oncology next month.   Vactosertib is a drug candidate that selecti...


Bio Institute Division: 1522-2375
Pharmaceutical Division: 02-3463-7111
Bio Institute Division: AICT Bldg., A, 145 Gwanggyo-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do 16229
Pharmaceutical Division: Daegwan Bldg., 190 Gangnam-daero, Seocho-gu, Seoul
Bio Institute Division: 031-888-9440
Pharmaceutical Division: 02-3463-8111
Bio Institute Division: bio@theragenetex.com
Pharmaceutical Division: etex@etexpharm.com